Shareholder
Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webinar
Joining the annual APMA 2021 Annual Scientific Meeting held from July 29 to August 1, was an important opportunity to share Hexima’s data on pezadeftide’s potential in the management of onychomycosis and discuss with leading physicians in this specialty. In the US,...
NailMail Q2 2021
Hexima Limited (ASX:HXL) is proud to release its “NailMail” quarterly activities report for the quarter ended 30 June 2021. Major achievements covered in this report: - Completing enrolment in phase IIb clinical trial for pezadeftide (formerly HXP124) as a treatment...
Media Interview and Presentation – Stockhead
Hexima CEO, Michael Aldrige, spoke with Stockhead as part of their V-Con video conference series focused on biotechs. V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading...
ShareCafe Webinar
Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 21 May 2021 at 12:30pm AEST. Mr Aldridge provided a company overview and discussed the strategic direction of Hexima, including the significance of the new INN designation and recognition...
R&D Investor Webinar
Thank you to those that joined us for our first R&D Webinar. We had a great response and an engaged audience. For those that missed it, you can view the full recording via the link below. Topics covered on the day included: The strong science behind HXP124 and how...
Australian Financial Review: Niche products best option for biotechs
Hexima is pleased to be featured in the Australian Financial Review (AFR) article which highlights the often challenging path for Australian biotechs from clinical trails to commercialisation. CEO, Michael Aldrige, explains why he thinks Hexima is positioned well to...
Bioshares Number 873
Hexima CEO, Michael Aldridge, and Chief Operating Officer, Nicole van der Weerden, were recently interviewed by Bioshares. Michael and Nicole spoke to Bioshares about HXP124 and why it is well suited to onychomycosis, the encouraging efficacy results so far, our trial...